Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 316 of 5804
-
New hope for cervical cancer patients who Can't take chemo
Disease control Not yet recruitingConcurrent chemoradiotherapy (CRT) is the standard of care for locally advanced cervical cancer (LACC). However, a substantial proportion of patients have contraindications to cisplatin based chemotherapy due to advanced age, renal impairment, cardiac dysfunction, or other comorb…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for aggressive breast cancer: targeted drug tested in organ crisis patients
Disease control Recruiting nowThe goal of this clinical trial is to learn if Trastuzumab Rezetecan (SHR-A1811) is safe and tolerable for patients with HER2-Low unresectable/metastatic breast cancer complicated with visceral crisis. Participants will take Trastuzumab Rezetecan every three weeks, until disease …
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Could a new drug combo wipe out three parasitic diseases at once?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if mass drug administration with moxidectin in combination with diethylcarbamazine, and albendazole (MoxDA) can treat lymphatic filariasis, scabies and strongyloidiasis in children and adults living in communities where these diseases a…
Phase: PHASE3 • Sponsor: Medicines Development for Global Health • Aim: Disease control
Last updated Jun 26, 2026 14:32 UTC
-
Stem cells could save sight after chemical burns
Disease control Not yet recruitingSevere chemical burns of the eye are serious injuries that can cause intense inflammation of the ocular surface and destroy limbal epithelial stem cells, which are essential for corneal healing. These injuries may lead to severe vision loss, blindness, or even loss of the eye des…
Phase: PHASE2 • Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New shot aims to cut COPD attacks in half
Disease control Not yet recruitingA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase: PHASE3 • Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for mild stroke: Clot-Buster may help when time is lost
Disease control Not yet recruitingTo verify the efficacy and safety of intravenous tenecteplase (TNK) in patients with disabling minor stroke and large vessel occlusion (LVO) within a 4.5-24 hour time window.
Phase: PHASE3 • Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could tailored tamoxifen doses keep more breast cancer patients on treatment?
Disease control Not yet recruitingIn Sweden, approximately 7000 women are diagnosed with hormone-sensitive breast cancer annually. According to international and national guidelines, most of these women are recommended anti-hormonal therapy for five to ten years to improve prognosis. Tamoxifen, one of the most wi…
Phase: PHASE3 • Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New stent trial aims to stop second strokes in Hard-to-Treat carotid disease
Disease control Recruiting nowGoal is to analyse the clinical safety and efficacy of the CARESTO® heal Stent within standard clinical routine for the treatment of patients with symptomatic non-stenotic carotid disease (SyNC) and with high-risk plaque features for stroke recurrence compared to medical treatmen…
Sponsor: Acandis GmbH • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail aims to stop cervical cancer return
Disease control Not yet recruitingThe goal of this clinical trial is to learn if the combination of Pembrolizumab and Lenvatinib works to treat locally advanced cervical cancer in adults that will undergo primary chemoradiation and brachytherapy. It will also learn about the safety of the combination of Pembroliz…
Phase: PHASE2 • Sponsor: Prof. Dr. Remi A. Nout • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Tumor avatars could personalize sarcoma therapy
Disease control ENROLLING_BY_INVITATIONThis study is a prospective single arm multicenter intervention study aimed at evaluating the feasibility of using organoid drug sensitivity results to guide first-line treatment of advanced leiomyosarcoma. The primary endpoint of the study is objective response rate (ORR). The s…
Phase: NA • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Custom-Made genetic drug tested in single ALS patient
Disease control Not yet recruitingThis research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New antibody combo targets tough lymphoma in early trial
Disease control Not yet recruitingThis is an open-label, multicenter, Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of EMB-07 combination therapy in adult patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL). The study consists tw…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug cocktail shows promise for recurrent ovarian cancer
Disease control Not yet recruitingThis is a prospective, open-label, single-arm, multicenter exploratory clinical study designed to evaluate the efficacy and safety of iparomlimab/tuvonralimab (QL1706), a bispecific antibody targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated pr…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New cholesterol drug QLC7401 enters final testing phase
Disease control Not yet recruitingTo evaluate the efficacy, safety and immunogenicity of QCL7401 subcutaneous administration in patients with primary hypercholesterolemia or mixed hyperlipidemia with poorly controlled LDL-C elevated on optimized lipid-lowering therapy.
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Double probe heat therapy could slash cervical cancer risk in HIV-Positive women
Prevention Not yet recruitingCervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the Wor…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 11:00 UTC
-
New stem cell combo aims to stop lymphoma from spreading to the brain
Disease control Recruiting nowIn the era of novel therapeutic agents, high-dose conditioning chemotherapy combined with autologous hematopoietic stem cell transplantation (auto-HSCT) remains an important and feasible consolidation strategy for non-Hodgkin lymphoma, especially for high-risk and relapsed/refrac…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug targets tough cancers with KRAS G12D mutation
Disease control Recruiting nowUNLOCK ASP3082 is an open label, single arm, multicenter, phase 2 platform study that aims to evaluate the mechanisms of action and resistance to ASP3082 in metastatic/locally advanced Non-Samll-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC) with the presenc…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Gene-Edited immune cells take on Hard-to-Treat myeloma in early trial
Disease control TerminatedThis phase Ib trial tests the safety, side effects and best dose of clustered regularly interspaced short palindromic repeats (CRISPR) delivered anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells (1XX BCMA CAR-T cells) in treating patients with multiple…
Phase: PHASE1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug duo targets hard-to-treat KRAS G12D cancers
Disease control Recruiting nowThis is a multicenter, open-label, Phase Ib/II clinical study. The study includes Phase Ib-Dose Exploration Stage and Phase II - Efficacy Exploration and Determination Stage.
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug duo aims to extend remission in advanced ovarian cancer
Disease control Not yet recruitingThis is a single-arm, open-label, multicenter exploratory clinical study designed to evaluate the efficacy and safety of fluzoparib combined with famitinib malate as maintenance therapy in patients with newly diagnosed advanced (FIGO III-IV) high-grade serous or endometrioid ovar…
Phase: PHASE2 • Sponsor: Jinhua Zhou • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC